AlphAIAlphAI — Financial news for AI agents
investing.comAUG 262 min read$SYRE

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

Original reporting
investing.com
Published Aug 26, 2026, 10:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 10:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$SYRE
Bearish
high confidence
Mentioned
$SYRE
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SYREBearishHigh
01

Why it matters

The announcement caused an 11.7% pre‑market decline, reflecting investor reassessment of the RA program's near‑term value.

02

Market read

The news is a primary catalyst for SYRE and illustrates the sensitivity of small‑cap biotech stocks to early‑stage trial outcomes.

03

What to watch

The data still validates TL1A inhibition, opening potential for combination therapies and other indications.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Spyre Therapeutics announced Phase 2 SKYWAY RA sub‑study results, noting both doses met statistical significance but fell short of internal thresholds.

Company-level read

Ticker impact

$SYREBearishHigh confidence
Context

Spyre Therapeutics shares fell 11.7% in pre‑market trading after the company disclosed Phase 2 RA sub‑study data showing insufficient efficacy to continue SPY072 as monotherapy.

Expected impact

Potential further decline of 5‑10% over the next few days if no positive catalyst emerges.

Evidence & confidence

Clinical readout is a primary catalyst; the market reacted immediately with a double‑digit pre‑market drop.

Market effects

Sector

Biotech sector may see heightened scrutiny of early‑stage autoimmune programs.

Regional

U.S. biotech stocks could face short‑term pressure.

Global

Limited to investors in biotech and specialty pharma.

Counterpoint

What could challenge this read

Wedbush maintains an Outperform rating, suggesting the pipeline's later readouts could offset the setback.

Key entities

  • company
    Spyre Therapeutics

    Biotech firm developing anti‑TL1A antibody SPY072.

  • analyst
    Wedbush

    Maintained Outperform rating with $130 price target.

Read at source← All news

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Spyre's SPY072 Shows Mixed Efficacy In Phase 2 RA Study, Fails Internal Bar For Monotherapy

Spyre Therapeutics (SYRE) reported mixed Phase 2 results for SPY072 in rheumatoid arthritis, showing efficacy but not meeting monotherapy targets. Both doses showed statistically significant benefits over placebo on some endpoints. The company plans to release data on other trials in 2026-2028. Wedbush maintains an outperform rating with a $130 price target. SYRE shares are down 4.06% in overnight trading.

rttnews.com2 min